Literature DB >> 9706050

Phase behavior of binary and ternary amorphous mixtures containing indomethacin, citric acid, and PVP.

Q Lu1, G Zografi.   

Abstract

PURPOSE: To better understand the nature of drug-excipient interactions we have studied the phase behavior of amorphous binary and ternary mixtures of citric acid, indomethacin and PVP, as model systems.
METHODS: We have prepared amorphous mixtures by co-melting or coprecipitation from solvents, and have measured glass transition temperatures with differential scanning calorimetry.
RESULTS: Citric acid and indomethacin in the amorphous state are miscible up to 0.25 weight fraction of citric acid, equivalent to about 2 moles of citric acid and 3 moles of indomethacin. Phase separation, as reflected by two Tg values, occurs without crystallization leading to a saturated citric acid-indomethacin amorphous phase and one essentially containing only citric acid. PVP-citric acid and PVP-indomethacin form non-ideal miscible systems at all compositions. A ternary system containing 0.3 weight fraction of PVP produces a completely miscible system at all citric acid-indomethacin compositions. The use of 0.2 weight fraction of PVP, however, only produces miscibility up to a weight fraction of 0.4 citric acid relative to indomethacin. The two phases above this point appear to contain citric acid in PVP and citric acid in indomethacin, respectively.
CONCLUSIONS: Two components of an amorphous solid mixture containing citric acid and indomethacin with limited solid state miscibility can be solubilized as an amorphous solid phase by the addition of moderate levels of PVP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9706050     DOI: 10.1023/a:1011983606606

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Properties of citric acid at the glass transition.

Authors:  Q Lu; G Zografi
Journal:  J Pharm Sci       Date:  1997-12       Impact factor: 3.534

Review 2.  Characteristics and significance of the amorphous state in pharmaceutical systems.

Authors:  B C Hancock; G Zografi
Journal:  J Pharm Sci       Date:  1997-01       Impact factor: 3.534

3.  Mixing behavior of colyophilized binary systems.

Authors:  S L Shamblin; L S Taylor; G Zografi
Journal:  J Pharm Sci       Date:  1998-06       Impact factor: 3.534

4.  Crystallization of indomethacin from the amorphous state below and above its glass transition temperature.

Authors:  M Yoshioka; B C Hancock; G Zografi
Journal:  J Pharm Sci       Date:  1994-12       Impact factor: 3.534

5.  Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions.

Authors:  L S Taylor; G Zografi
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

6.  Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates.

Authors:  M Yoshioka; B C Hancock; G Zografi
Journal:  J Pharm Sci       Date:  1995-08       Impact factor: 3.534

7.  The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids.

Authors:  B C Hancock; G Zografi
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

8.  The relationship between the glass transition temperature and water vapor absorption by poly(vinylpyrrolidone)

Authors:  C A Oksanen; G Zografi
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

  8 in total
  11 in total

1.  Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: stability of a vaccine.

Authors:  Ahmad M Abdul-Fattah; Vu Truong-Le; Luisa Yee; Emilie Pan; Yi Ao; Devendra S Kalonia; Michael J Pikal
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

2.  Solid-State NMR Investigation of Drug-Excipient Interactions and Phase Behavior in Indomethacin-Eudragit E Amorphous Solid Dispersions.

Authors:  Joseph W Lubach; Jonathan Hau
Journal:  Pharm Res       Date:  2018-02-20       Impact factor: 4.200

3.  Evaluation of drug-polymer miscibility in amorphous solid dispersion systems.

Authors:  Alfred C F Rumondor; Igor Ivanisevic; Simon Bates; David E Alonzo; Lynne S Taylor
Journal:  Pharm Res       Date:  2009-09-22       Impact factor: 4.200

4.  Pharmaceutical Co-Crystals, Salts, and Co-Amorphous Systems: A Novel Opportunity of Hot Melt Extrusion.

Authors:  Sagar Narala; Dinesh Nyavanandi; Priyanka Srinivasan; Preethi Mandati; Suresh Bandari; Michael A Repka
Journal:  J Drug Deliv Sci Technol       Date:  2020-11-09       Impact factor: 3.981

5.  Freeze Dried Quetiapine-Nicotinamide Binary Solid Dispersions: A New Strategy for Improving Physicochemical Properties and Ex Vivo Diffusion.

Authors:  Ahmed Mahmoud Abdelhaleem Ali; Mayyas Mohammad Ahmad Al-Remawi
Journal:  J Pharm (Cairo)       Date:  2016-11-30

6.  Amorphous-Amorphous Phase Separation in API/Polymer Formulations.

Authors:  Christian Luebbert; Fabian Huxoll; Gabriele Sadowski
Journal:  Molecules       Date:  2017-02-15       Impact factor: 4.411

7.  Fluoroquinolone Amorphous Polymeric Salts and Dispersions for Veterinary Uses.

Authors:  Hanah Mesallati; Anita Umerska; Lidia Tajber
Journal:  Pharmaceutics       Date:  2019-06-09       Impact factor: 6.321

8.  Predicting process design spaces for spray drying amorphous solid dispersions.

Authors:  Stefanie Dohrn; Pranay Rawal; Christian Luebbert; Kristin Lehmkemper; Samuel O Kyeremateng; Matthias Degenhardt; Gabriele Sadowski
Journal:  Int J Pharm X       Date:  2021-02-25

9.  Multiple glass transitions and freezing events of aqueous citric acid.

Authors:  Anatoli Bogdan; Mario J Molina; Heikki Tenhu; Thomas Loerting
Journal:  J Phys Chem A       Date:  2014-12-19       Impact factor: 2.781

10.  Co-Amorphous Screening for the Solubility Enhancement of Poorly Water-Soluble Mirabegron and Investigation of Their Intermolecular Interactions and Dissolution Behaviors.

Authors:  Ji-Hun An; Changjin Lim; Alice Nguvoko Kiyonga; In Hwa Chung; In Kyu Lee; Kilwoong Mo; Minho Park; Wonno Youn; Won Rak Choi; Young-Ger Suh; Kiwon Jung
Journal:  Pharmaceutics       Date:  2018-09-05       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.